Endocrine Abstracts

BackgroundPembolizumab is a highly specific, monoclonal antibody directed against the programmed cell death receptor, PD-1 and its ligand PD-L1. It is licenced as an immunotherapy for use in locally advanced or metastatic urothelial cell carcinoma, amongst other malignancies. Whilst rare, endocrinopathies, including thyroid dysfunction, are recognised side effects of immunotherapy such as Pembroluzimab. However, hyperthyroidism is much less common than h...

Title – Testosterone replacement Therapy (TRT) and prostate cancer Hypogonadism is a condition with low serum testosterone level, which can manifest as depression, lack of libido, decreased bone mineral density and muscle weakness In patients with hypogonadism returning serum testosterone to normal levels results in improvement in cognition, mood, sexual function, physical performance, normalises bone density and erythropoiesis.Case<p class="abs...